Browse recruiting and upcoming clinical trials for Dravet syndrome.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIChildren aged 2 to <18 years with a clinical diagnosis of Dravet syndrome and an SCN1A variant who meet seizure and prior-treatment requirements.
What is being studied AIIntrathecal zorevunersen versus sham to test effects on seizures and neurodevelopment
Who can join AIAdults 18–65 with Absence Epilepsy (with or without Eyelid Myoclonia/Jeavons) or a Developmental and Epileptic Encephalopathy such as Dravet or Lennox‑Gastaut.
What is being studied AITests oral BMB-101 twice daily to evaluate effects on seizures and EEG.
Who can join AIPeople age 3 and older with Dravet syndrome or Lennox‑Gastaut syndrome whose neurologist plans to start them on fenfluramine and who have not taken it before.
What is being studied AIWhether reduced-montage home EEG plus vital signs helps clinicians during fenfluramine titration.
Who can join AIPeople (ages 0–30) with genetic epilepsy‑dyskinesia syndromes or related childhood movement disorders linked to pathogenic/likely pathogenic variants.
What is being studied AICollects clinical data and blood, urine, and skin samples to study epilepsy-dyskinesia syndromes.
Who can join AIChildren (0–18 years) with epilepsy and a movement disorder (epilepsy-dyskinesia syndromes) and a pathogenic or likely pathogenic variant in one of the listed genes.
What is being studied AICollects retrospective clinical and genetic data on epilepsy-dyskinesia syndromes.
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIChildren 6 months to less than 2 years with genetically confirmed CDKL5 deficiency disorder and treatment‑resistant seizures (≥8 in 28 days).
What is being studied AITests ganaxolone as an add-on treatment for seizures in young children with CDD.